Can betahistine be given twice daily (BID) for vestibular disorders?

Can Betahistine Be Given Twice Daily (BID)?

Yes, betahistine can be given twice daily (BID), and this dosing regimen has been shown to be equally effective and well-tolerated as three-times-daily dosing for vestibular disorders.

Evidence for BID Dosing

Equivalent Efficacy to TID Dosing

• A randomized, open-label study of 120 patients with Ménière's disease directly compared betahistine 24 mg BID versus 16 mg TID over 24 weeks and found no significant difference in efficacy between the two regimens 1
• Both dosing schedules showed significant improvement in vertigo severity, frequency, and duration from baseline (p < 0.01) 1
• Adverse event profiles were comparable between groups, with headache being the most common side effect (maximum 16.7% of patients), and the incidence decreased over time 1

Modified-Release Formulation

• A newer modified-release betahistine formulation (48 mg once daily) has been shown to be non-inferior to betaserc 24 mg BID in a double-blind randomized trial of 264 patients with Ménière's disease or vestibular vertigo 2
• Both groups showed significant DHI (Dizziness Handicap Inventory) score reductions of approximately 32 points after 12 weeks (p<0.001) 2
• The once-daily formulation may improve patient adherence while maintaining comparable safety 2

Dosing Recommendations by Condition

For Ménière's Disease

• Standard dosing options include 24 mg BID or 16 mg TID, both providing similar clinical outcomes 1
• The American Academy of Otolaryngology-Head and Neck Surgery guideline lists betahistine as a treatment option for Ménière's disease, though notes that the 2020 BEMED trial (the highest quality study) found no significant difference between betahistine (48 mg/day or 144 mg/day) and placebo in reducing vertigo attacks over 9 months 3
• Despite the BEMED trial's negative findings, betahistine remains widely used, and when prescribed, a total daily dose of 48 mg divided BID is a reasonable approach 3

For Other Vestibular Disorders

• For benign paroxysmal positional vertigo (BPPV), betahistine 24 mg BID for 10 days has been studied, though it did not show superiority over repositioning maneuvers alone 4
• For peripheral vestibular vertigo, betahistine 16 mg BID for 3 months significantly improved vertigo frequency, intensity, and duration compared to placebo 5
• For uncompensated unilateral vestibulopathy, higher doses (72 mg/day) may be more effective than standard doses (36 mg/day) in facilitating vestibular compensation 6

Practical Dosing Algorithm

Start with betahistine 24 mg BID (total 48 mg/day) for initial treatment:

• This provides equivalent efficacy to TID dosing with improved convenience 1
• Continue for at least 3 months, as most studies used 2-12 week treatment periods, with the most robust trial extending to 9 months 3, 5

If inadequate response after 4 weeks at standard dose:

• Consider increasing to 36 mg BID (total 72 mg/day) for patients with intractable symptoms, particularly in uncompensated unilateral vestibulopathy 6

Reassess regularly:

• Monitor for symptom improvement or stabilization as well as medication tolerance 3
• Discuss titrating down or stopping once symptoms subside, though optimal duration is unclear 3

Safety Considerations

• Use with caution in patients with asthma or history of peptic ulcer disease; avoid in patients with pheochromocytoma 3
• Common side effects include headache, balance disorder, nausea, nasopharyngitis, feeling hot, eye irritation, palpitations, and upper gastrointestinal symptoms 3
• Serious adverse effects are rare 3

Important Caveats

• The highest quality recent evidence (BEMED trial, 2020) showed betahistine was not superior to placebo for Ménière's disease, which represents the best available evidence despite contradicting earlier meta-analyses 3
• The American Academy of Otolaryngology-Head and Neck Surgery guideline committee states they are "unable to make a definitive statement on use of betahistine to control MD symptoms" given the conflicting evidence 3
• However, given betahistine's favorable safety profile and some evidence of benefit in other vestibular conditions, BID dosing remains a reasonable clinical option when medication is deemed appropriate 1, 5